Released Aug 4, 2016, after the close
10-Q filed Aug 4, 2016, 35 days after period end · 0001193125-16-671775
Q2 2016 · 10-Q
Revenue$59.00K$59.00K −60.7% vs Q2 2015no prior Q1 2016 on file
Net Income-$30.16M-$30.16M N/M vs Q2 2015N/M vs Q1 2016
EPS Diluted-$0.84-$0.84 N/M vs Q2 2015N/M vs Q1 2016
Operating Income-$30,476,000N/M
Operating Cash Flowderived-$20,894,000N/M
Free Cash Flowderived-$20,900,000N/M
Margins · derived
Operating margin-51654.2%−29645.6 pt vs Q2 2015
Net margin-51115.3%−29318.6 pt vs Q2 2015
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q2 2016 | Q2 2015 | Q2 2014 | Q2 2013 |
|---|---|---|---|---|
| Revenue | $59.00K | $150.00K | $21.00K | $133.00K |
| Net Income | -$30.16M | -$32.70M | -$16.43M | — |
| EPS Diluted | -$0.84 | -$0.92 | -$0.55 | -$2.86 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Karyopharm Therapeutics Inc. · CIK 1503802 · Engraved from SEC EDGAR